Source: CureToday articles
Among patients with non–muscle-invasive bladder cancer, neoadjuvant mitomycin demonstrated favorable safety.
Recent Content
- Asembia AXS25: Community Pharmacists Can Optimize Specialty Pharmacy Care
- Asembia AXS25: Balancing Innovation With Affordability Crucial for Sustainable Rare Disease Economic Models
- Asembia AXS25: Advancing nAMD and DME Treatments: Pharmacists’ Role in Patient Care and Therapy Optimization
- Asembia AXS25: Navigating the Evolving Landscape of GLP-1 Medications
- Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis
- Investigational LUT014 Gel Improves Acneiform Rash in Patients With Metastatic Colorectal Cancer
- Alternating Glivec and Stivarga Doesn’t Improve Advanced GIST Outcomes
- A Dose of Inspiration: Celebrating the Pharmacist-Patient Relationship During Patient Experience Week
- Breast MRI Offers Sensitive Imaging for High-Risk and Diagnosed Patients
- Neoadjuvant Mitomycin C Shows Favorable Safety in Bladder Cancer